What is Oxford Genetics?
Oxford Genetics LTD operates as a specialized biotechnology enterprise headquartered in the United Kingdom. The company has carved out a distinct market position by focusing on the production of versatile cloning plasmids, which serve as essential tools for academic research and industrial biotechnology applications. By providing high-quality genetic engineering solutions, Oxford Genetics supports the broader scientific community in advancing complex biological research.
The company's operational model is deeply rooted in innovation, utilizing its proprietary technology to streamline genetic workflows. As a key supplier in the biotech supply chain, its market position is defined by its ability to bridge the gap between fundamental research and scalable commercial application, ensuring that researchers have access to the precise genetic tools required for modern molecular biology.
How much funding has Oxford Genetics raised?
Oxford Genetics has raised a total of $13.8M across 6 funding rounds:
Other Financing Round
$228K
Other Financing Round
$778K
Unspecified
$2M
Multiple Rounds
$10.8M
Other Financing Round (2013): $228K with participation from Mercia Fund Management
Other Financing Round (2015): $778K led by Mercia Fund Management
Unspecified (2016): $2M supported by Mercia Technologies
Other Financing Round (2017): $500K featuring Innovate UK
Other Financing Round (2017): $645K backed by Mercia Technologies
Other Financing Round (2017): $9.7M with participation from Invesco and Mercia Technologies
Key Investors in Oxford Genetics
Mercia Technologies
Mercia Asset Management provides equity and debt financing to UK businesses with growth ambitions, acting as investment partners from scale-up to exit.
Invesco
Invesco Ltd. is a global, publicly owned investment manager providing comprehensive portfolio management services across equity, fixed income, and alternative asset classes.
Innovate UK
Innovate UK is a government-backed innovation agency that provides funding and support to businesses to drive economic growth through technological advancement.
What's next for Oxford Genetics?
With the recent infusion of capital, Oxford Genetics is poised to enter a new phase of enterprise-level scaling. The strategic focus will likely shift toward expanding its product portfolio and enhancing its manufacturing capacity to meet the growing global demand for high-fidelity genetic materials. By maintaining its commitment to research excellence, the company is expected to deepen its integration into the global biotech ecosystem.
Future growth will likely be driven by the optimization of its cloning platforms and the potential for new collaborative ventures. As the company matures, the emphasis will remain on sustaining its competitive advantage through technological differentiation and strategic partnerships, ensuring that it remains at the forefront of the rapidly evolving biotechnology industry.
